OSE Immunotherapeutics - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

HanAll F&B files rice noodle patent after 6 tonnes of testing as Korea seeks new uses for domestic rice

HanAll F&B plans rice pasta and naengmyeon expansion after filing patent for improved noodle manufacturing

Infographic showing EPACK Prefab Technologies Limited’s ₹100 crore Ghiloth manufacturing facility in Rajasthan, highlighting commercial production, expanded pre-engineered building and insulated-panel capacity, and existing panel utilisation of 49.5%.

EPACK Prefab Technologies expands Rajasthan manufacturing capacity with Rs 1,376cr order book, but margins remain under pressure

Infographic showing Molecular Partners’ plan to cut up to 55 jobs, or about 44% of its workforce, while refocusing on targeted radiotherapy and lead Radio-DARPin candidate MP0712 ahead of expected efficacy data in 2027.

Molecular Partners (NASDAQ: MOLN) plans 44% workforce cut as MP0712 becomes central to strategy

Australia budget update faces fresh pressure as inflation hits 4.3%

Read More

Healthcare Industry News

Why OSE Immunotherapeutics stock is moving after Marc Le Bozec replaces Nicolas Poirier as CEO

OSE Immunotherapeutics ousts CEO Nicolas Poirier, names Marc Le Bozec interim chief and launches a strategic review. See what it means for investors.

byPallavi Madhiraju

October 3, 2025

web analytics